Stock Events

Tandem Diabetes Care 

€36.75
60
+€0+0% Wednesday 06:00

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
2.85B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

30OctExpected
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Next
-1.92
-1.37
-0.82
-0.27
Expected EPS
-0.41037
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TD5A.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Dexcom
DXCM
Mkt Cap27.79B
Dexcom produces continuous glucose monitoring systems, directly competing in the diabetes management space with Tandem's insulin pumps.
Insulet
PODD
Mkt Cap14.22B
Insulet Corporation offers the Omnipod, an insulin management system that competes with Tandem's insulin pump products.
Medtronic
MDT
Mkt Cap113.61B
Medtronic is a major player in the diabetes care market, offering insulin pumps and continuous glucose monitoring systems that compete with Tandem's offerings.
Abbott Laboratories
ABT
Mkt Cap197.08B
Abbott Laboratories produces the FreeStyle Libre, a continuous glucose monitoring system, competing in the broader diabetes management market.
Senseonics
SENS
Mkt Cap208.39M
Senseonics Holdings offers the Eversense CGM system, a direct competitor in the continuous glucose monitoring market.
Thermo Fisher Scientific
TMO
Mkt Cap234.95B
Thermo Fisher Scientific, through its life sciences solutions, indirectly competes in the diabetes care market by providing technologies and supplies that support diabetes research and diagnostics.
Novo Nordisk
NVO
Mkt Cap620.4B
Novo Nordisk is a leading global healthcare company that, while primarily known for its diabetes medications, also invests in diabetes care devices and solutions, positioning it as a broader competitor.
Sanofi
SNY
Mkt Cap141.43B
Sanofi is involved in diabetes care through its insulin and glucose monitoring solutions, making it a competitor in the diabetes management space.
Baxter International
BAX
Mkt Cap19.36B
Baxter International offers medical devices that, while not directly competing in the insulin pump or CGM markets, provide various healthcare solutions that can be used in diabetes care.
Johnson & Johnson
JNJ
Mkt Cap399.26B
Johnson & Johnson, through its medical devices and pharmaceutical segments, has interests in the diabetes market, making it a broader competitor in the healthcare space for diabetes management.

Analyst Ratings

54.67Average Price Target
The highest estimate is €75.
From 12 ratings within the last 6 months. This is not an investment recommendation.
Buy
83%
Hold
17%
Sell
0%

About

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Show more...
CEO
Mr. John F. Sheridan
Employees
2400
Country
US
ISIN
US8753722037
WKN
000A2H5BX

Listings